RhuMab 2C4

DRUG3 trials

Sponsors

Genentech, Inc., Hoffmann-La Roche

Conditions

NeoplasmsSolid Tumor

Phase 1

Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors

CompletedNCT00027027

Genentech, Inc.Neoplasms

Start: 2001-11-30End: 2003-08-31Updated: 2015-07-27

A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors

CompletedNCT02490475

Hoffmann-La RocheSolid Tumor

Start: 2004-02-29End: 2006-04-30Updated: 2017-05-17

A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors

CompletedNCT02494596

Hoffmann-La RocheSolid Tumor

Start: 2004-01-31End: 2005-09-30Updated: 2015-11-10